Why is Titan Biotech falling/rising?

As of 15-Jul, Titan Biotech Ltd's stock price is currently at Rs 454.60, reflecting a decrease of Rs 10.2 or 2.19%. The stock has underperformed its sector by 3.28% today, following a trend reversal after two consecutive days of gains. It reached an intraday low of Rs 448.2, indicating a decline of 3.57%. Over the past week, the stock has seen a slight decline of 0.74%, while it has performed better over the past month with a gain of 5.96%. However, the stock's year-to-date performance shows a significant drop of 37.96%, and it has underperformed the market over the last year with a return of -24.23%. The company has high management efficiency with a return on equity (ROE) of 25.08% and a low debt-to-equity ratio, but it has declared negative results for the last three consecutive quarters, which has contributed to its poor long-term growth outlook.
In the broader market context, the Sensex has declined by 1.36% over the past week, indicating that while Titan Biotech's short-term performance is slightly better than the benchmark, it still lags behind in the longer term. The stock's performance over the past year is starkly negative compared to the market's slight gain of 0.37%. This underperformance is compounded by the company's declining profits and high valuation metrics, such as a price-to-book value of 2.4, which is considered expensive compared to its peers. The falling investor participation, as evidenced by a significant drop in delivery volume, further suggests a lack of confidence among investors, contributing to the stock's current downward trajectory.